Arrotex Pharmaceuticals has partnered with India’s Stelis Biopharma in its $500 million pitch to build a technology park in Victoria that can manufacture multiple types of vaccines including mRNA.

According to its expression of interest put to the government and viewed by The Australian Financial Review, Arrotex will lead an international partnership with the Bangalore-based global vaccine specialty manufacturer, which will be an equity investor in the facility capable of producing about 460 million doses of mRNA vaccines and 205 million doses of synthetic protein or viral vector vaccines annually.